AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06796855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Onabotulinum Toxin A Injection
Description: Participants in this arm will receive a single dose of 100 units of Onabotulinum Toxin A injected into 10 sites on the bladder wall using a 4mm injection needle and 19F rigid cystoscope. The injection is administered under local anesthesia in an outpatient setting. The Onabotulinum Toxin A is diluted in sterile saline and delivered into the detrusor muscle, aiming to reduce detrusor overactivity and urgency symptoms. Patients undergo urinary ultrasound and post-void residual volume (PVR) assessment on postoperative day 1 before discharge. No additional doses are administered, and follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
Study NCT06791421 — intervention group
Intervention type: OTHER
Intervention: AI-Predictng Model
Description: The intervention in this study involves an AI-based predictive model designed to analyze and integrate patient electronic health records (EHR), clinical lab results, and multimodal imaging data (e.g., X-rays, MRIs, CT scans). The AI model is trained to predict a patient's genotype based on these non-genetic data sources. This model uses machine learning algorithms to detect patterns and infer genetic information that would traditionally require direct genetic testing. There are no active treatments or genetic tests involved in this intervention; rather, the AI system serves as a tool to predict genetic information from available clinical data, offering a non-invasive and potentially more accessible alternative to genetic testing.
Study NCT04692649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic posterior capsular stretch
Description: pragmatic posterior stretch is used to increase the length of the posterior capsule
Study NCT04692649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross body stretch
Description: crossbody stretch performed by an individual
Study NCT05705765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instability training
Description: Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
Study NCT05229003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg or 10mg, d1-9，q2w
Study NCT05229003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200mg, d6, q2w
Study NCT05229003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m2, d6, q2w
Study NCT05239624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
Study NCT05239624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
Study NCT05275920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Alert (BPA)
Description: A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
Study NCT05275920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Basket Message
Description: An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
Study NCT05437588 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
Study NCT04899544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)
Description: Pivotal Response Treatment in autism center.
Study NCT06110468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoreDISTParticipation
Description: CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
Study NCT03960099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pictograph in Banner and Verification Alert
Description: Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
Study NCT05874414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561 + Trametinib
Description: GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
Study NCT05115864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFMT with device
Description: The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
Study NCT06260631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser acupuncture and Exercise therapy program
Description: The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises.
Study NCT06260631 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises.
Study NCT06514794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-CART-007
Description: A single IV infusion of WU-CART-007 cells on Day 1
Study NCT04810546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarrow Formulas Oral Bovine Lactoferrin Supplement
Description: Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
Study NCT04844879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextAR TKA system
Description: The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
Study NCT05517655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xe
Description: Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
Study NCT06192433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (40Hz)
Description: Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
Study NCT06192433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)
Description: Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
Study NCT05929833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)
Description: The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.
Study NCT05929833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
Study NCT06343818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff
Description: Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
Study NCT05678816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREATHER
Description: respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
Study NCT05532592 — intervention group
Intervention type: OTHER
Intervention: Perceptions and attitudes towards COVID-19 and COVID-19 vaccine
Description: Attitude towards COVID-19; Knowledge about COVID-19 vaccine
Study NCT04571970 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
Study NCT06797570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Strategy for Side Effect Counseling in ADHD Treatment
Description: One group receives negatively framed and extensive information about the most common adverse events of methylphenidate. A fixed script will be prepared for the treating paediatrician, and the same information will be provided in written form. The other group receives positively framed and concise information about the most common adverse events of methylphenidate. This information will also be provided in written form.
Study NCT05597176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Cord Injury Exercise Group
Description: Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
Study NCT06795737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Description: The experimental group's protocol consists of two stages: in-hospital Phase I and post-discharge self-training. For Phase I, cardiac and rehab specialists assess NYHA classification, muscle strength, and mobility to create an exercise plan, supervised by therapists and nurses. Phase II involves twice-weekly outpatient rehab for 24 sessions and weekly remote guidance with WeChat and wristbands to track vitals, totaling 12 remote sessions. Exercise prescriptions are customized based on 6MWTD outcomes, with ongoing support from rehab staff and nurses.
Study NCT06795737 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional rehabilitation
Description: Health Education: Nurses provide manuals on heart failure causes, treatment, diet, exercise (detailing frequency, intensity, duration, types, and safety), and self-monitoring to control group patients.~Outpatient Follow-up: Post-discharge, heart failure patients have follow-ups at 2 weeks, 1 month, 2 months, and 3 months. A multidisciplinary team of doctors, pharmacists, and nurses handles these, with doctors for assessment, pharmacists for medication education, and nurses for self-care assessment and education.
Study NCT05678816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy prgramme for rehabilitation of stroke patients
Description: physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training.
Study NCT05678816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy prgramme for rehabilitation of stroke patients
Description: physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training.
Study NCT06797583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Photobiomodulation (TPBM)
Description: CytonBrite, 1064nm LED
Study NCT06797583 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial photobiomodulation (TPBM)
Description: Sham condition using a randomized block design involving 2 (TPBM): 1(sham) randomization.
Study NCT06793228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystalline Megestrol Acetate
Description: Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
Study NCT06509997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003 combined with Dalpicicilip
Description: MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
Study NCT05156099 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Scanning
Description: The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
Study NCT05156099 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Scanning - 2 months later
Description: The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
Study NCT05317715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group A, who will complete a questionnaire before receiving information about intrauterine devices
Description: Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
Study NCT05317715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group B who will answer a questionnaire after having the information about the intrauterine devices
Description: Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
Study NCT04985500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: peripheral nerve block
Study NCT04985500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIF block
Description: peripheral nerve block
Study NCT04985500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guidance
Study NCT04985500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 10-20 mL of 0.25% bupivacaine
Study NCT06486493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
Study NCT06486493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playful Family Education Strategy
Description: Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity.
Study NCT06486493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced Playful Family Education Strategy
Description: The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
Study NCT06793228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nanocrystalline Megestrol Acetate
Description: Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
Study NCT06793228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)
Study NCT06793228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PTOC
Description: Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
Study NCT06350136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With Tele-Nursing
Description: no With Tele-Nursing
Study NCT06793748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PEP-TISSEEL
Description: Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
Study NCT06793748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TISSEEL Fibrin Sealant KIT
Description: Fibrin Sealant (TISSEEL® VH SD Kit)
Study NCT04899544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)
Description: Pivotal Response Treatment in home environment.
Study NCT06563479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FMISO-PET Scan
Description: Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
Study NCT06563479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FMISO-PET Scan
Description: Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
Study NCT06794801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）
Description: In the experimental arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successfully prepared lesions will be treated with a drug-coated autoperfusion balloon dilatation catheter (DCAB). Successful lesion preparation is defined as post-pretreatment residual stenosis ≤ 30%, no type C dissections, intravascular imaging confirming no significant residual plaque burden at the dissection site, no transverse expansion > 60°, no longitudinal expansion > 2 mm, no dissection involving the media or adventitia, and no location at the stent distal end. There should be no hematoma and no significant thrombus (TIMI thrombus burden grade ≤ 2). If the angiographic and intravascular imaging results after DCAB treatment are unsatisfactory, an emergency drug-eluting stent (DES) will be implanted.